• Advised biotech startup on development of microneedle-based wearable sensor for the electrochemical detection of methadone.

• Involved in the seminal development of ZL Bio's multi-layer, wire-based electrochemical biosensor particularly the electroactive interferent blocking, and glucose limiting membrane (GLM) layers, their pre-exposure to sterilizing gas and the impact on sensor performance.• Responsible for identifying viable TPU polyurethane source; comprehensive characterization and testing of TPU polyurethane-based GLM solutions; worked closely with Manufacturing to optimize GLM formulations based on sensor performance feedback results. • Assisted in optimizing ZL Bio's Manufacturing process by troubleshooting and reducing variability; utilized DOEs and other methods to identify and set critical process parameters, improving performance, yield and scalability. • Provided applicator and wearable analysis of ex-planted sensors for ZL Bio's In-House Clinical Studies team; performed “autopsies” to identify root causes and opportunities for improving sensor design.

• Developed microneedle-based sensor array for continuous glucose monitoring; responsible for implementing a viable spray-coating method for applying the GLM layer onto the microneedle arrays.• Liaised with 3rd party vendors in evaluating and securing potential polyurethane materials.

• Built analytical lab to support Dexcom’s Sensor Membrane R&D effort; identified and acquired needed analytical equipment, expanding Dexcom’s material characterization capabilities to include GPC, DSC, HPLC, GC, DLS, Moisture Meter, Instron, Durometer, Potentiometric Titrator and Rheometer.• Implemented new analytical equipment and standardized test methods to characterize existing and new raw materials; characterized Dexcom's TPU polyurethane library, providing insight into the impact of polyurethane structure on sensor performance and manufacturing robustness.• Closely involved in all stages of analytical testing as mandated by Dexcom’s Quality System from IOQ execution through Test Method Validation (Test Procedures, SOPs, Lab Bench Reports, Product Specification Requirements).

• Owned and operated a small, eco-friendly inn on the island of Eleuthera in the Bahamas. • Worked in concert with Bahamian manager, involved in all aspects of the Inn’s successful day-to-day operation.

• Assessed technical viability of R&D projects related to novel biodegradable PolyEsterAmide (PEA) based polymer; negotiated corporate partnerships via acquisition, collaboration and/or licensing agreements. Functioned as technical liaison on all PEA-based projects, providing material and technical support. Evaluated safety, efficacy and drug release kinetics of PEA-drug formulations in a porcine model.

• Conjugation of various peptides and PEG species to enhance biocompatibility of PEA; developed series of polymer-drug formulations for drug delivery applications to meet target drug release profile and/or biodegradation rate requirements. Contributed to successful licensing deals to Guidant Corp and Boston Scientific Corp, together valued at $170 million. Delivered first public presentation of MediVas’ biopolymer technology at TCT conference, Sept 2003.

• Supervised synthesis, purification, characterization, process design, development and scale-up of monomers/polymers, polymer-drug conjugation and formulations. Evaluated structure-property relationships of polyesteramides; established SOPs and identified performance specifications for PEA polymer.

• Synthesized material for 2002 NOBLESSE First-in-Man clinical trial to evaluate MediVas' PEA-Tempo polymer for coronary stent applications. Pioneered early efforts to attach drugs to PEA polymer, establishing standard protocol for paclitaxel conjugation to PEA.

• First post-doc to join lab of Assistant Professor Eric Sorenson investigating the rational design and chemical synthesis/characterization of novel, mechanism-based β-lactamase inhibitors.

• Conducted contract research of metallocene-catalyzed poly(propylene) syntheses for Amoco and British Petroleum, utilizing high-pressure autoclave, liquid- and gas-phase stereoregular techniques. Designed and installed new monomer/solvent purification station as well as 500mL and 1-gallon stainless steel autoclave reactors.